Wang S, Chen J, Guo XZ. KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(8): 1388-1405 [PMID: 36160748 DOI: 10.4251/wjgo.v14.i8.1388]
Corresponding Author of This Article
Xiao-Zhong Guo, PhD, Chief Doctor, Chief Physician, Director, Professor, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. guoxiaozhong1962@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1388-1405 Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1388
KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers
Shuo Wang, Jiang Chen, Xiao-Zhong Guo
Shuo Wang, Jiang Chen, Xiao-Zhong Guo, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China
Author contributions: Wang S wrote the original draft; Chen J and Guo XZ contributed to the review and manuscript editing.
Supported bythe National Natural Science Foundation of China, No. 81672465; and the Science and Technology Program of Liaoning Province, No. 2019JH8/10300080.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Zhong Guo, PhD, Chief Doctor, Chief Physician, Director, Professor, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. guoxiaozhong1962@126.com
Received: November 11, 2021 Peer-review started: November 11, 2021 First decision: December 27, 2021 Revised: January 6, 2022 Accepted: July 22, 2022 Article in press: July 22, 2022 Published online: August 15, 2022
Core Tip
Core Tip: The KAI1/CD82 gene inhibits the metastasis of most tumors and is significantly correlated with their invasion and prognosis. According to our recent pre-experimental results, we speculated that KAI1/CD82 might inhibit the migration and metastasis of cancer cells by regulating autotaxin (ATX)-lysophosphatidic acid (LPA) axis. However, no relevant research has been reported. To clarify the mechanism of ATX-LPA in KAI1/CD82 inhibition of cancer metastasis will provide an important theoretical basis for targeted cancer therapy, and further research is necessary. In this paper, the molecular composition of the KAI1/CD82 gene and ATX-LPA axis, their physiological functions in tumors, and their roles in gastrointestinal cancers and target therapy are reviewed.
